Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin versus dacarbazine in previously treated advanced soft tissue sarcoma
ACTRN12611001074987Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS), Liposarcoma and leiomyosarcoma (LMS) comparing Eribulin with Dacarbazine (2 arms). Primary endpoint: Overall survival. Started Mar 2011; status: completed.
02
Drugs
eribulindacarbazine
03
Conditions
soft tissue sarcoma (STS)Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on ACTRN12611001074987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001074987.